This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
International journal of pharmaceutics, 609, 121154-121154 (2021-10-09)
Bacterial biofilms are a huge burden on our healthcare systems worldwide. The lack of specificity in diagnostic and treatment possibilities result in difficult-to-treat and persistent infections. The aim of this in vitro study was to investigate if microbubbles targeted specifically
Vancomycin-induced interstitial nephritis superimposed on coexisting renal disease: the importance of renal biopsy.
Michael S Gelfand et al.
The American journal of the medical sciences, 347(4), 338-340 (2014-03-22)
Treating Clostridium difficile infection.
Daniel M Shafran et al.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 186(7), 531-531 (2013-12-18)
The Journal of infectious diseases, 209(9), 1446-1451 (2013-11-13)
Whole-genome sequencing was used to determine whether the reductions in recurrence of Clostridium difficile infection observed with fidaxomicin in pivotal phase 3 trials occurred by preventing relapse of the same infection, by preventing reinfection with a new strain, or by
The Journal of infectious diseases, 209(8), 1231-1240 (2014-01-10)
Staphylococcus aureus is the most common cause of endovascular infections. The staphylococcal accessory regulator A locus (sarA) is a major virulence determinant that may potentially impact methicillin-resistant S. aureus (MRSA) persistence in such infections via its influence on biofilm formation.